Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check5 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check26 days agoChange DetectedThe website has updated the type of intervention and added contact information for the National Cancer Institute Referral Office, while removing the previous version's details.SummaryDifference0.7%
- Check55 days agoChange DetectedThe website has been updated to version v2.13.3, with new additions dated from December 10 to December 12, 2024, while the previous version v2.13.2 and several earlier dates have been removed.SummaryDifference0.5%
- Check62 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information on who to contact for questions about joining the study and where it is taking place, with a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check69 days agoChange DetectedRecent additions include three new dates in November 2024, while three earlier dates from September and October 2024 have been removed.SummaryDifference0.5%
Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.